FDA eligibility criteria for GLP-1 weight medications
The FDA-approved labelling for weight-management GLP-1 drugs requires either: (a) BMI ≥ 30 kg/m² (obesity), or (b) BMI ≥ 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes or prediabetes, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease.
This criteria applies to Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg). Note that Ozempic and Mounjaro are approved for type 2 diabetes management and are sometimes prescribed off-label for weight loss — different criteria may apply.